A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers.

Trial Profile

A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 May 2014

At a glance

  • Drugs Ridaforolimus (Primary) ; Bevacizumab
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors ARIAD Pharmaceuticals; Merck & Co
  • Most Recent Events

    • 26 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Results have been presented at the Joint Multidisciplinary Congress of the 15th annual European Cancer Organisation (ECCO) and the 34th annual European Society of Medical Oncology (ESMO), according to a ARIAD pharmaceuticals media release.
    • 28 Jul 2009 Status changed from recruiting to active, no longer recruiting. Information reported in an ARIAD Pharmaceuticals media release states patient enrolment has been completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top